|Bid||199.00 x 800|
|Ask||200.49 x 800|
|Day's Range||198.01 - 203.62|
|52 Week Range||166.30 - 211.90|
|Beta (3Y Monthly)||0.89|
|PE Ratio (TTM)||15.81|
|Forward Dividend & Yield||5.80 (2.85%)|
|1y Target Est||N/A|
Alexion Pharmaceuticals is likely "on the radar" as a takeover candidate, but biotech company Amgen doesn't fit logically as an acquirer, an analyst said. Alexion stock toppled Friday.
On August 21, Spanish website Intereconomia reported that Amgen would be announcing its acquisition of Alexion Pharmaceuticals in the next few days.
Amgen (AMGN) markets Mvasi and Kanjinti, biosimilar versions of Avastin and Herceptin, respectively in the United States, and Kanjinti and Amgevita, biosimilar of Humira, in the EU.
Rumors of an imminent acquisition of Alexion Pharmaceuticals sent the stock jumping, and while a that may not pan out, SVB Leerink thinks a more-concrete deal may be in the drug maker’s future.
Biotech giant Amgen could be nearing a deal to buy Alexion Pharmaceuticals at a 74% premium, according to a Spanish news outlet. The deal values Alexion stock at $200 a share.
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
It’s been a tough year for (AMGN) stock, which has made a recent rally all the more welcome for investors. Expect that trend to continue, predicts Jefferies, which believes the tide is finally turning for the drug maker. Amgen (ticker: AMGN) stock is up less than 5% year to date through Wednesday’s close, compared to a nearly 17% gain for the S&P 500, and a 10% rise for the (IBB) (IBB).
Amgen (AMGN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Medicines Company (NASDAQ: MDCO) stock has staged a nice recovery in the first half of 2019 after a steep 60% pullback in the second half of 2018 that dragged it to a 52-week low of $16.69 on Dec. 21. Medicines Co. is a biopharma with a single-point focus of tackling cardiovascular diseases. About 17.3 million deaths occur globally due to cardiovascular diseases, with 854,000 of these in the U.S., according to the company, which cited WHO estimates.
Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.
An analyst downgraded shares of biotechs Amgen and Celgene on Monday, saying both stocks are nearing appropriate values. Amgen stock ran up after a judge sided with it in a patent battle.
AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.
Analysts at Mizuho seem to have a love/hate relationship with drugmaker Amgen after downgrading the stock in a note Monday while also raising the company's price target. The firm lowered Amgen to neutral from buy while also raising its price target to $212 from $208. The stock closed Friday's session at $204.02, with the new price target representing a potential 4% upside from the closing price.
The topsy-turvy ride for stock traders continues this morning with U.S. stock futures pointing toward a sizeable down gap at the open. Yesterday's gains are being completely unwound.Source: Shutterstock Heading into the open, futures on the Dow Jones Industrial Average are down 1.46%, and S&P 500 futures are lower by 1.42%. Nasdaq-100 futures have lost 1.57%.In the options pits, call volume spiked sharply yesterday underlying the excitement surrounding the market rally. Specifically, about 19.9 million calls and 17.5 million puts changed hands on the session.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe enthusiasm was felt at the CBOE as well, with the single-session equity put/call volume ratio falling to 0.66. Meanwhile, the 10-day moving average held its ground at 0.74. Based on the wickedness of today's open, however, I suspect both metrics to end with bearish readings today.Options traders came after calls throughout the session, boosting volumes in Amgen (NYSE:AMGN), American Airlines Group (NYSE:AAL) and Apple (NASDAQ:AAPL).Let's take a closer look: Amgen (AMGN)The direction of Amgen shares reversed in a big way this week after the biotech behemoth won a patent dispute against Novartis (NYSE:NVS). Over the past three sessions, AMGN stock has rocketed 12% higher on massive volume. The rally pushed shares back to last year's highs, and they now stand a whisper from breaking out to record levels. * 15 Growth Stocks to Buy for the Long Haul In the short run, AMGN is extended and deserving of a breather. Consolidation or a pullback will allow its moving averages to catch-up and make for a more sustainable uptrend. That said, any weakness should be viewed as a buying opportunity.On the options trading front, traders went cuckoo for calls. Activity ballooned to 1,314% of the average daily volume, with 275,296 total contracts traded; 96% of the trading came from call options alone. The catalyst for such a groundswell in call demand is the company's looming ex-dividend date. Amgen's next quarterly payment of $1.45 will be paid out to shareholders of record and investors used call options to snatch-up short-term control of the stock to gain access to the payout.Implied volatility has been falling this week and now sits at 24% or the 29th percentile of its one-year range. Premiums are baking in daily moves of $3.08 or 1.5%, so set your expectations accordingly. American Airlines (AAL)The news was light for American Airlines Group, but that didn't prevent traders from swarming its options. In an otherwise ordinary day, we saw options activity jump to 270% of the average daily volume, with 107,237 total contracts traded. Calls slightly outpaced puts to claim 55% of the session's sum.Ever since last month's earnings took the wind out of its sails, AAL stock has been declining. It has now lost 21% in three weeks and will soon test its 52-week low at $27.02. Of course, weakness isn't new for AAL. It has been in a cyclical decline for two years and has already lost over 53% of its value. Until we see resistance levels breached, buyers should cast their lines elsewhere. There are much more attractive fish to catch.Implied volatility remains, tucked near the middle of its 2019 range. It's at 41% or the 31st percentile, and premiums are pricing in daily moves of 71 cents or 2.6%. Apple (AAPL)Apple stock led the charge during Tuesday's roaring rally in the Nasdaq for one simple reason. It dodged Chinese tariffs for this year's iPhones. Here's the skinny if you want all the details.Before we get too excited over yesterday's jump, keep in mind the overnight whacking for stocks is taking a bite out of Apple's gains. The stock is set to open down 2.4%. Time will tell if the positive news is enough to keep AAPL stock aloft while the rest of the market grapples with growing recession concerns. * 7 Stocks the Insiders Are Buying on Sale The post-earnings slide found support at $192.50, so that's the line in the sand to watch. If broken, this year's ascent is in a heap of trouble. Until then, ignore the chop and focus on the bigger picture, which still points higher.On the options trading front, traders favored calls throughout the day. Total activity swelled to 137% of the average daily volume, with 686,707 contracts traded. Calls added 59% to the day's take.With uncertainty easing, implied volatility sunk to 29% or the 35th percentile of its one-year range. That means traders are now pricing in daily movement of $3.87 or 1.9%.As of this writing, Tyler Craig didn't hold a position in any of the aforementioned securities. Check out his recently released Bear Market Survival Guide to learn how to defend your portfolio against market volatility. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy for the Long Haul * 5 More Cloud Stocks With Plenty of Potential * 5 Clean Energy ETFs to Buy for 2019 The post Wednesday's Vital Data: Amgen, American Airlines and Apple appeared first on InvestorPlace.
Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Amgen stock is the IBD Stock Of The Day after the biggest biotech company prevailed in a patent battle against Novartis subsidiary Sandoz, protecting nearly $5 billion in 2019 U.S. sales.